Peter L Thompson
Overview
Explore the profile of Peter L Thompson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
2660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Bijl M, van der Veen J, Fiolet A, Boersma E, Cornel J, Eikelboom J, et al.
J Am Heart Assoc
. 2025 Feb;
14(5):e040412.
PMID: 39996509
No abstract available.
2.
Kha R, Min H, Marschner S, Mahendran S, Thiagalingam A, Poulter R, et al.
Heart
. 2025 Jan;
PMID: 39819620
Background: Coronary heart disease (CHD) remains a leading cause of mortality and disability worldwide. Approximately half of the patients who have had a prior hospital admission for CHD will have...
3.
Mohammadnia N, van Broekhoven A, Bax W, Eikelboom J, Mosterd A, Fiolet A, et al.
Eur J Prev Cardiol
. 2024 Oct;
PMID: 39478683
Aims: Inflammatory lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) on lipoproteins convey residual cardiovascular disease risk. The LoDoCo2 (low-dose colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events...
4.
Stewart R, Robledo K, Tonkin A, Keech A, Kritharides L, Marschner I, et al.
J Am Heart Assoc
. 2024 Oct;
13(21):e034367.
PMID: 39450716
Background: Protein biomarkers that reflect different pathophysiological pathways have been associated with the risk of adverse cardiovascular events. However, it is uncertain whether these associations are sustained with increasing years...
5.
Fiolet A, Poorthuis M, Opstal T, Amarenco P, Boczar K, Buysschaert I, et al.
EClinicalMedicine
. 2024 Oct;
76:102835.
PMID: 39431112
Background: Guidelines recommend low-dose colchicine for secondary prevention in cardiovascular disease, but uncertainty remains concerning its efficacy for stroke, efficacy in key subgroups and about uncommon but serious safety outcomes....
6.
Radavelli-Bagatini S, Bondonno C, Dalla Via J, Sim M, Gebre A, Blekkenhorst L, et al.
Nat Commun
. 2024 Oct;
15(1):8126.
PMID: 39402045
Provision of non-invasive vascular imaging results to individuals has been shown to improve cardiovascular disease risk factor control: its impact on diet remains uncertain. In this two-arm, single-blind, parallel, 12-week...
7.
Psaltis P, Nguyen M, Singh K, Sinhal A, Wong D, Alcock R, et al.
Cardiovasc Res
. 2024 Aug;
PMID: 39189611
Background: Low-dose colchicine reduces the risk of cardiovascular events after myocardial infarction (MI). The purpose of this study was to assess the effect of colchicine post-MI on coronary plaque morphology...
8.
Fiolet A, Keusters W, Blokzijl J, Nidorf S, Eikelboom J, Eikelboom J, et al.
Eur Heart J Qual Care Clin Outcomes
. 2024 Mar;
11(1):89-96.
PMID: 38486357
Aims: Recent trials have shown that low-dose colchicine (0.5 mg once daily) reduces major cardiovascular events in patients with acute and chronic coronary syndromes. We aimed to estimate the cost-effectiveness...
9.
10.
Belhoul-Fakir H, Brown M, Thompson P, Hamzah J, Jansen S
Clin Ther
. 2023 Oct;
45(11):1092-1098.
PMID: 37891144
Purpose: The occurrence and development of atherosclerotic cardiovascular disease, which can result in severe outcomes, such as myocardial infarction, stroke, loss of limb, renal failure, and infarction of the gut,...